丙型肝炎病毒 NS5B拇指部位 II 抑制剂中羧酸基团的生物异位取代:苯丙氨酸衍生物

IF 6 2区 医学 Q1 CHEMISTRY, MEDICINAL
{"title":"丙型肝炎病毒 NS5B拇指部位 II 抑制剂中羧酸基团的生物异位取代:苯丙氨酸衍生物","authors":"","doi":"10.1016/j.ejmech.2024.116832","DOIUrl":null,"url":null,"abstract":"<div><p>Hepatitis C virus (HCV) is a global health concern and the NS5B RNA-dependent RNA polymerase (RdRp) of HCV is an attractive target for drug discovery due to its role in viral replication. This study focuses on NS5B thumb site II inhibitors, specifically phenylalanine derivatives, and explores bioisosteric replacement and prodrug strategies to overcome limitations associated with carboxylic acid functionality. The synthesized compounds demonstrated antiviral activity, with compound <strong>6d</strong> showing the most potent activity with an EC<sub>50</sub> value of 3.717 μM. The hydroxamidine derivatives <strong>7a-d</strong> showed EC<sub>50</sub> values ranging from 3.9 μM to 11.3 μM. However, the acidic heterocyclic derivatives containing the oxadiazolone (<strong>8a-d</strong>) and oxadiazolethione (<strong>9a-d</strong>) rings did not exhibit measurable activity. A methylated heterocycle <strong>10b</strong> showed a hint of activity at 8.09 μM. The pivaloyloxymethyl derivatives <strong>11a</strong> and <strong>11b</strong> did not show antiviral activity. Further studies are warranted to fully understand the effects of these modifications and to explore additional strategies for developing novel therapeutic options for HCV.</p></div>","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":null,"pages":null},"PeriodicalIF":6.0000,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Bioisosteric replacement of the carboxylic acid group in Hepatitis-C virus NS5B thumb site II inhibitors: phenylalanine derivatives\",\"authors\":\"\",\"doi\":\"10.1016/j.ejmech.2024.116832\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Hepatitis C virus (HCV) is a global health concern and the NS5B RNA-dependent RNA polymerase (RdRp) of HCV is an attractive target for drug discovery due to its role in viral replication. This study focuses on NS5B thumb site II inhibitors, specifically phenylalanine derivatives, and explores bioisosteric replacement and prodrug strategies to overcome limitations associated with carboxylic acid functionality. The synthesized compounds demonstrated antiviral activity, with compound <strong>6d</strong> showing the most potent activity with an EC<sub>50</sub> value of 3.717 μM. The hydroxamidine derivatives <strong>7a-d</strong> showed EC<sub>50</sub> values ranging from 3.9 μM to 11.3 μM. However, the acidic heterocyclic derivatives containing the oxadiazolone (<strong>8a-d</strong>) and oxadiazolethione (<strong>9a-d</strong>) rings did not exhibit measurable activity. A methylated heterocycle <strong>10b</strong> showed a hint of activity at 8.09 μM. The pivaloyloxymethyl derivatives <strong>11a</strong> and <strong>11b</strong> did not show antiviral activity. Further studies are warranted to fully understand the effects of these modifications and to explore additional strategies for developing novel therapeutic options for HCV.</p></div>\",\"PeriodicalId\":314,\"journal\":{\"name\":\"European Journal of Medicinal Chemistry\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":6.0000,\"publicationDate\":\"2024-09-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Medicinal Chemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S022352342400713X\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S022352342400713X","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

摘要

丙型肝炎病毒(HCV)是全球关注的健康问题,由于其在病毒复制中的作用,HCV 的 NS5B RNA 依赖性 RNA 聚合酶(RdRp)是一个具有吸引力的药物发现靶点。本研究重点关注 NS5B拇指位点 II 抑制剂,特别是苯丙氨酸衍生物,并探索生物异构替代和原药策略,以克服与羧酸功能相关的限制。合成的化合物具有抗病毒活性,其中化合物 6d 的 EC50 值为 3.717 μM,活性最强。羟脒衍生物 7a-d 的 EC50 值从 3.9 μM 到 11.3 μM 不等。然而,含有噁二唑酮环(8a-d)和噁二唑硫酮环(9a-d)的酸性杂环衍生物没有表现出可测量的活性。甲基化杂环 10b 在 8.09 μM 时显示出一丝活性。新戊酰氧基甲基衍生物 11a 和 11b 没有显示出抗病毒活性。为了充分了解这些修饰的效果,并探索开发新型 HCV 治疗方案的其他策略,我们有必要开展进一步的研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Bioisosteric replacement of the carboxylic acid group in Hepatitis-C virus NS5B thumb site II inhibitors: phenylalanine derivatives

Bioisosteric replacement of the carboxylic acid group in Hepatitis-C virus NS5B thumb site II inhibitors: phenylalanine derivatives

Hepatitis C virus (HCV) is a global health concern and the NS5B RNA-dependent RNA polymerase (RdRp) of HCV is an attractive target for drug discovery due to its role in viral replication. This study focuses on NS5B thumb site II inhibitors, specifically phenylalanine derivatives, and explores bioisosteric replacement and prodrug strategies to overcome limitations associated with carboxylic acid functionality. The synthesized compounds demonstrated antiviral activity, with compound 6d showing the most potent activity with an EC50 value of 3.717 μM. The hydroxamidine derivatives 7a-d showed EC50 values ranging from 3.9 μM to 11.3 μM. However, the acidic heterocyclic derivatives containing the oxadiazolone (8a-d) and oxadiazolethione (9a-d) rings did not exhibit measurable activity. A methylated heterocycle 10b showed a hint of activity at 8.09 μM. The pivaloyloxymethyl derivatives 11a and 11b did not show antiviral activity. Further studies are warranted to fully understand the effects of these modifications and to explore additional strategies for developing novel therapeutic options for HCV.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
11.70
自引率
9.00%
发文量
863
审稿时长
29 days
期刊介绍: The European Journal of Medicinal Chemistry is a global journal that publishes studies on all aspects of medicinal chemistry. It provides a medium for publication of original papers and also welcomes critical review papers. A typical paper would report on the organic synthesis, characterization and pharmacological evaluation of compounds. Other topics of interest are drug design, QSAR, molecular modeling, drug-receptor interactions, molecular aspects of drug metabolism, prodrug synthesis and drug targeting. The journal expects manuscripts to present the rational for a study, provide insight into the design of compounds or understanding of mechanism, or clarify the targets.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信